Cutting-Edge Collaboration: Sony, SCREEN, and VitroVo Unveil Revolutionary Microelectrode Array System
In a significant leap forward for medical research and drug development, Japan’s technological titans, Sony Semiconductor Solutions Corporation, SCREEN Holdings Co., Ltd., and VitroVo Inc., have announced the creation of an innovative microelectrode array (MEA) system. This advanced system, featuring a high-density CMOS-MEA equipped with an astounding 237,000 electrodes, promises to revolutionize the way cellular activity is measured, recorded, and visualized, particularly in the realms of neuronal and cardiac disease research and drug discovery.
The Technological Marvel: High-Density CMOS-MEA
The core of this groundbreaking system lies in its high-density CMOS-MEA technology. But what exactly does this entail? At its essence, CMOS-MEA is a device that employs complementary metal-oxide-semiconductor (CMOS) technology integrated with a microelectrode array to detect the electrical activity of cells. By measuring the electrical potential produced by ions moving in and out of cells, this system can visualize cellular activity in real-time, providing highly detailed image data.
The specific CMOS-MEA being developed by Sony sets itself apart with a significantly reduced pitch between electrodes. This design choice results in a compact yet densely packed array of approximately 237,000 electrodes, allowing for simultaneous data collection from all electrodes. This high-density data acquisition capability facilitates high-definition monitoring of cellular behavior, which was previously unachievable with traditional technologies.
A Synergistic Collaboration
The development of this MEA system is a testament to the powerful synergy between Sony, SCREEN, and VitroVo, in partnership with the Tohoku Institute of Technology. Each company brings its own expertise to the table. Sony’s advanced sensing devices and high-density CMOS-MEA technology form the backbone of the system. SCREEN contributes its expertise in measuring cellular electrical activity, while VitroVo lends its knowledge in compound evaluation and data analysis.
This collaboration enables the system to detect extracellular electrical potentials through its dense array of microelectrodes. The data is then output as image data, enabling researchers to observe cellular activity at a single-cell level. This level of detail allows for the differentiation between healthy and diseased cells and assesses cellular responses to various compounds.
Transforming Drug Development and Disease Research
In the ever-evolving field of drug research and development, the need for accurate efficacy assessment and safety evaluation methods is critical. Traditional animal testing methods are not only time-consuming but also raise ethical concerns. The newly developed MEA system offers a viable alternative, facilitating the precise evaluation of compound effects on human cells without relying on animal testing.
The acquisition of sophisticated cellular data through this system is expected to significantly contribute to disease research, especially in understanding disease phenotypes. This includes research into mental health disorders such as depression and schizophrenia, as well as neurological disorders like amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. The system’s ability to provide detailed insights into neuronal activity makes it an invaluable tool for neuroscience research and drug development targeting these conditions.
Preparing for Commercialization
To validate the system’s effectiveness and promote technological advancements toward commercialization, Sony, SCREEN, and VitroVo are offering the MEA system on a trial basis to corporations and research institutions involved in drug development. SCREEN will provide the system, while VitroVo will support its implementation by offering consulting services on cell culture procedures, custom data analysis, and result interpretation.
Additionally, VitroVo will offer contract research services to verify the system’s effectiveness, allowing users to provide feedback that will aid in further system development and market analysis. This trial phase is a strategic step towards the commercialization of MEA systems utilizing CMOS-MEA technology.
Beyond Drug Discovery: Broader Applications
While the primary focus of the MEA system is on drug discovery and disease research, its applications extend beyond these fields. Joint research between Sony and Tohtech has shown that the CMOS-MEA can facilitate cell monitoring and data analysis at the single-cell level, a feat that was previously challenging with conventional methods. This opens up possibilities for its use in various disciplines such as biotechnology, biomedical science, medicine, and pharmacology.
Key Roles in System Development
Each company involved in the system’s development plays a crucial role:
- Sony: Responsible for hardware development, including the provision of the CMOS-MEA sensor.
- SCREEN: Develops software for cellular data measurement and analysis, and provides customer support during the trial offering.
- VitroVo: Offers contracted research services using the system, consults on culture and analysis, and develops new utilization and analysis technologies.
Technical Insights and Further Reading
For those interested in delving deeper into the technical aspects of the CMOS-MEA technology and its applications, several related publications are available. These include studies on large-area field potential imaging using 236,880 electrodes CMOS-MEA technology and field potential imaging in human iPSC-derived cardiomyocytes. Such resources provide valuable insights into the capabilities and potential of this cutting-edge technology.
Conclusion
The joint efforts of Sony, SCREEN, and VitroVo in developing this advanced MEA system highlight the potential for technological innovation to drive significant advancements in medical research and drug development. By providing detailed insights into cellular activity and offering an alternative to traditional animal testing methods, this system stands to make a substantial impact on the future of medical science.
For more information on this exciting development, visit the official announcement page: Sony Semiconductor Solutions Corporation.
In summary, this collaboration not only showcases the power of combining expertise across different fields but also promises to transform the landscape of disease research and drug development in the years to come.
For more Information, Refer to this article.
